Screener
Corcept Therapeutics CORT Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Long-term marketable securities | 236,451 | 160,270 |
| Other assets | 2,946 | 5,153 |
| Deferred tax assets, net | 178,680 | 168,197 |
| Total assets | $888,702 | $836,651 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $14,910 | $40,444 |
| Accrued research and development expenses | 21,628 | 33,954 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's total assets?
- Corcept Therapeutics (CORT) reported total assets of $888.7M in Q2 2026.
- How has Corcept Therapeutics's total assets changed year-over-year?
- Corcept Therapeutics's total assets increased by 10.8% year-over-year, from $801.72M to $888.7M.
- What is the long-term trend for Corcept Therapeutics's total assets?
- Over 5 years (2020 to 2025), Corcept Therapeutics's total assets has grown at a 7.9% compound annual growth rate (CAGR), from $571.73M to $836.65M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Corcept Therapeutics's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude